Triple

T22651389
Position Surface form Disambiguated ID Type / Status
Subject Regulation (EC) No 1394/2007 E559101 entity
Predicate assignsRoleTo P16628 FINISHED
Object Committee for Advanced Therapies — NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Committee for Advanced Therapies | Statement: [Regulation (EC) No 1394/2007, assignsRoleTo, Committee for Advanced Therapies]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Committee for Advanced Therapies
Context triple: [Regulation (EC) No 1394/2007, assignsRoleTo, Committee for Advanced Therapies]
  • A. Committee for Advanced Therapies chosen
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • B. Committee on Development, Regeneration and Stem Cell Biology
    The Committee on Development, Regeneration and Stem Cell Biology is an academic program at the University of Chicago focused on research and graduate training in developmental biology, tissue regeneration, and stem cell science.
  • C. Office of Tissues and Advanced Therapies
    The Office of Tissues and Advanced Therapies is a U.S. FDA office responsible for regulating cellular and gene therapies, tissue-based products, and other advanced biologic treatments.
  • D. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • E. Center for Cellular and Molecular Therapeutics
    The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e245489dd88190b1f674acf61c8769 completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1703c5538819089d9b5349f26ea6d completed April 29, 2026, 2:43 a.m.
Created at: April 17, 2026, 3:06 p.m.